Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses-Reference-Cited by-同舟云学术

Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses

Published:2018-09-21 Issue:12 Volume:7 Page:e1500671
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Quandt Jasmin¹²,Schlude Christoph¹,Bartoschek Michael¹³^ORCID,Will Rainer⁴,Cid-Arregui Angel¹⁵,Schölch Sebastian⁶⁷^ORCID,Reissfelder Christoph⁶⁷,Weitz Jürgen⁸,Schneider Martin⁶,Wiemann Stefan⁴⁹^ORCID,Momburg Frank¹¹⁰,Beckhove Philipp¹¹¹

Affiliation:

1. Department of Translational Immunology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany

2. Knapp Research Center, Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, USA

3. Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden

4. Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany

5. Targeted Tumor Vaccines Group, Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany

6. Department of Visceral Surgery, University Hospital Heidelberg, Heidelberg, Germany

7. Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

8. Department of Visceral, Thoracic, and Vascular Surgery, Medizinische Fakultaet an der TU-Dresden, Dresden, Germany

9. Division Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany

10. Antigen Presentation and T/NK Cell Activation Group, Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center (DKFZ), Heidelberg, Germany

11. Regensburg Center for Interventional Immunology (RCI), University Regensburg and Department of Hematology-Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1500671

Reference78 articles.

1. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

2. Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis

3. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

4. MUC1 Immunobiology: From Discovery to Clinical Applications

5. NY‐ESO‐1: Review of an Immunogenic Tumor Antigen

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for HPV negative head and neck squamous cell carcinoma;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. P18: Novel Anticancer Peptide from Induced Tumor-Suppressing Cells Targeting Breast Cancer and Bone Metastasis;Cancers;2024-06-15

3. Local Enrichment with Convergence of Enriched T-Cell Clones Are Hallmarks of Effective Peptide Vaccination against B16 Melanoma;Vaccines;2024-03-22

4. Neoantigen cancer vaccines: a new star on the horizon;Cancer Biology & Medicine;2023-12-29

5. Advances in biosynthesis of peptide drugs: Technology and industrialization;Biotechnology Journal;2023-11-14